BioStock: Coegin Pharma on the cusp of initiating COAK Study
Nordic biotech Coegin Pharma reached a key milestone this summer by receiving the green light from the Danish Medicines Agency to begin the Copenhagen Actinic Keratosis Study with lead candidate AVX001. Now, the company has also received a conditional approval from the Ethics Committee, meaning that the clinical trial will be initiated after making slight adjustments to patient information material. BioStock spoke with Coegin’s CEO Tore Duvold to discuss what this all means.
Read the interview with Tore Duvold at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/